A Phase II multicenter, randomized trial to compare anastrazole plus gefitinib with anastrazole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC)

Reviewer: Arpi Thukral, MD
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 1 de junio del 2008

Translation for this article does not exist